What happened with CLDI today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Calidi Biotherapeutics focuses on engineering viruses to reach tumors and deliver cancer treatments. Its business depends substantially on RedTail, a platform designed to carry modified viruses through the bloodstream to sites where cancer has spread. A cell-membrane envelope is intended to help the virus avoid immune clearance so it can replicate in tumor tissue and deliver genetic medicines. Its lead candidate, CLD-401, is designed to produce an immune-stimulating protein within tumors, but remains in early development and has not been given to humans. Calidi also develops treatments that use stem cells to carry viruses to tumors.
Calidi has no approved product and earns no revenue from product sales. Investors and lenders, rather than drug customers, currently provide its main funding, and continued operations depend on raising more capital. It cannot sell its candidates before regulatory approval; future product revenue depends on successful clinical development, approval and coverage and reimbursement from government and private healthcare payors.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Genelux Corporation is a close rival to Calidi in cancer-killing vaccinia viruses: Genelux is testing intravenous Olvi-Vec, while Calidi designs RedTail to reach tumors throughout the body. Watch Olvi-Vec’s intravenous lung-cancer trials for evidence on this delivery approach in patients, versus Calidi’s reported animal-model results.
Replimune Group, Inc. competes with Calidi to develop cancer treatments using tumor-killing viruses to stimulate immunity. RP1’s development and approval progress is the thing to watch: through the fiscal year ended March 31, 2026, Replimune had no approved products or product-sale revenue.
Candel Therapeutics, Inc. competes with Calidi in engineered viral cancer therapies, with overlap in brain-tumor programs and viruses carrying immune-stimulating genes. Watch linoserpaturev’s trial in recurrent high-grade glioma, including repeat dosing, as a concrete comparison for Calidi’s NeuroNova brain-tumor program.
Oncolytics Biotech, Inc.’s viral cancer treatment pelareorep competes with Calidi’s engineered tumor-killing viruses. Watch whether partners fund its larger trials in exchange for product rights and a share of sales proceeds; those agreements would offer a concrete gauge of partnering demand for viral cancer treatments.
CG Oncology, Inc. rivals Calidi’s immune-stimulating viral approach with cretostimogene, a virus designed to multiply in bladder tumors and carry the immune-stimulating gene GM-CSF. Its results in high- and intermediate-risk non-muscle-invasive bladder cancer provide a clinical comparison for Calidi’s viruses carrying immune-stimulating payloads.
Ernexa Therapeutics Inc. offers a competing route to delivering immune stimulants into tumors: its engineered stem cells secrete IL-7 and IL-15, while Calidi’s CLD-401 is designed to express an IL-15 superagonist and its legacy platforms carry viruses in stem cells. Watch ERNA-101’s ovarian-cancer development, keeping in mind that its reported tumor-growth and survival benefits remain preclinical.
ImmunityBio, Inc. provides a commercial reference for Calidi’s IL-15 strategy: it sells the IL-15 superagonist ANKTIVA, while Calidi’s CLD-401 is designed to produce an IL-15 superagonist inside tumors. Watch ANKTIVA sales for use with BCG in adults with BCG-unresponsive non-muscle-invasive bladder cancer in situ, with or without papillary tumors—not as proof that Calidi’s viral delivery works.
ImmunityBio, Inc. earningsIBRX
ImmunityBio's report will show sales of its IL-15 drug ANKTIVA for a specific bladder-cancer population, giving Calidi a commercial reference for its IL-15 strategy but not proof that Calidi's delivery works.
Look at ANKTIVA sales for adults with BCG-unresponsive non-muscle-invasive bladder cancer in situ, with or without papillary tumors. Stronger sales would show commercial demand for that approved use and offer a demand reference for Calidi's CLD-401, designed to produce an IL-15 superagonist inside tumors. Weaker sales would make that reference less encouraging. Neither outcome tests whether Calidi's virus delivers the payload or works.
Calidi Biotherapeutics, Inc. earningsThis company
Calidi has no approved products and relies on financing to fund development, so this report will show whether cash use and financing needs are still squeezing work on its drug candidates.
Read cash used in operations alongside cash on hand, then see whether financing filled the gap. Lower operating cash use with cash holding up would suggest current funds are buying more time for candidate development. If cash keeps shrinking and operations still require stock sales or borrowing, development remains exposed to financing availability and dilution.
